• Explore /
  • Poster
  • / ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma.

ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma.

Abstract Poster

Authors

null

Kristine Peregrino Lacuna

Columbia University Irving Medical Center, New York, NY

Kristine Peregrino Lacuna , Shing M Lee , Liner Ge , Mihaela Druta , Anthony Paul Conley , Mary Louise Keohan , Mark Agulnik , Melissa Amber Burgess , Anna Weinberg Chalmers , Gina Z. D'Amato , Benjamin Powers , Mahesh Seetharam , Brittany L Siontis , Mia C. Weiss , Sminu (Sam) Bose , Tahir Sheikh , Richard Piekarz , Gary K. Schwartz , Matthew Ingham

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Bone Tumors

Clinical Trial Registration Number

NCT04340843

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 11531)

DOI

10.1200/JCO.2023.41.16_suppl.11531

Abstract #

11531

Poster Bd #

465

Abstract Disclosures

Similar Posters

First Author: Jay Oza

First Author: Shubham Pant

First Author: Dong-Sheng Zhang

First Author: Yaobin Lin